Clinical Trial Update: A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 PET/CT imaging study in patients receiving enzalutamide for castration-resistant prostate cancer with bone metastases has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostate Carcinoma Metastatic to the Bone

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-05-05